BMS-536924 is an ATP-competitive inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) with an IC50 of 100 nM; it exhibits moderate inhibitory activity against FAK, MEK, and Lck, but minimal activity against Akt1 and MAPK1/2. It suppresses IGF-1R signaling, inhibits ligand-induced phosphorylation of ERK1/2, GSK3β, and Akt, and blocks both IGF-I-stimulated and basal IGF-1R activity in MCF10A cells. BMS-536924 demonstrates antiproliferative effects in various cancer cell lines, including TC32, HT1080/S, SK-LMS-1, H513, CTR, Rh41, and Rh36, and induces apoptosis by upregulating PDCD4 expression and promoting cleavage of PARP and caspase-3. In vivo, it shows potent antitumor activity in IGF-1R-driven Sal tumor models and unmodified Colo205 human colon cancer xenografts upon oral administration (100–300 mg/kg, once or twice daily). It significantly inhibits tumor growth in nude mice bearing TGBC-1TKB cell-derived xenografts and reduces CD8-IGF-1R-MCF10A xenograft tumor volume by 76% after two weeks of treatment (100 mg/kg). BMS-536924 also enhances insulin secretion in response to glucose challenge without causing significant toxicity, as evidenced by no adverse effects on body weight or glucose levels in treated mice.